Chengda Pharmaceuticals Hits Day Low of CNY 33.25 Amid Price Pressure

Chengda Pharmaceuticals Co., Ltd. experienced significant volatility on July 17, 2026, with the stock declining by 12.85% and reaching an intraday low of CNY 33.25. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by only 3.05% on the same day. Over the past week, Chengda's stock has decreased by 9.73%, while its monthly performance shows a decline of 6.01%. Despite these short-term setbacks, the company has demonstrated a notable annual return of 31.69%, significantly outperforming the China Shanghai Composite's 7.03% gain over the same period. Financial metrics indicate that Chengda Pharmaceuticals is facing challenges, with a low Return on Capital Employed (ROCE) of 7.29%, reflecting limited profitability relative to its capital. Additionally, the company has reported a modest annual sales growth rate of 2.38% over the last five years, alongside a concerning operating profit decline of 160.14%. Despite these hurdles, recent quarterly results have shown positive trends, including substantial growth in pre-tax and net profits. However, the stock's current trading position remains risky compared to its historical valuations.